Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of ACP-196 in Combination With Obinutuzumab for Patients With Relapsed / Refractory or Untreated CLL/SLL/PLL

NCT02296918 is registered in ClinicalTrials.gov with Acerta Pharma BV as lead sponsor.

NCT NCT02296918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02296918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of ACP-196 in Combination With Obinutuzumab for Patients With Relapsed / Refractory or Untreated CLL/SLL/PLL
Lead sponsor
Acerta Pharma BV
Phase
Phase 1
Overall status
Completed
Start date
December 22, 2014
Completion date
October 22, 2025
Enrollment
69 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, prolymphocytic leukemia, small lymphocytic lymphoma